Dr Reddy's Laboratories Ltd (RDY)

40.85
NYSE : Health Care
Prev Close 40.70
Day Low/High 40.45 / 40.97
52 Wk Low/High 39.04 / 54.73
Avg Volume 276.10K
Exchange NYSE
Shares Outstanding 165.73M
Market Cap 6.75B
EPS 1.80
P/E Ratio 22.99
Div & Yield 0.30 (0.70%)

Latest News

Dr. Reddy's And Integra LifeSciences Enter Into An Agreement To Market And Distribute DuraGen Plus® And Suturable DuraGen® Dural Regeneration In India

Dr. Reddy's And Integra LifeSciences Enter Into An Agreement To Market And Distribute DuraGen Plus® And Suturable DuraGen® Dural Regeneration In India

Dr. Reddy's Laboratories Limited (BSE:500124, NSE:DRREDDY, NYSE:RDY) and Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that they have entered into an...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AG, AMZN, CBPX, CTLT, FSM, GOLD, LADR, OHI Downgrades: ESRX, GCO, NXPI, OPB, PIP, RDY, TM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy's Q3 And 9M FY17 Financial Results

Dr. Reddy's Q3 And 9M FY17 Financial Results

Dr. Reddy's Laboratories Ltd.

INVESTOR ALERT: Investigation Of Dr. Reddy's Laboratories Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Dr. Reddy's Laboratories Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether certain statements issued during 2015 by Dr.

Dr. Reddy's To Release Q3 FY17 Results On Feb 4, 2017

Dr. Reddy's To Release Q3 FY17 Results On Feb 4, 2017

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Third Quarter and 9 months ended December 31, 2016 on Saturday, February 4, 2017 after the Board Meeting.

Dr. Reddy's Laboratories Announces The Launch Of Nystatin And Triamcinolone Acetonide Cream, USP In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Nystatin And Triamcinolone Acetonide Cream, USP In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Nystatin and Triamcinolone Acetonide Cream, USP, in the United States market, approved by the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CCJ, CMC, DF, DLNG, GATX, PCH, PFNX, PRAH, RDY, TMHC, VLO Downgrades: AKRX, BETR, EDGW, HLTH, KNDI, PRMW, SONC, VWR Initiations: RGNX Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy's Laboratories Announces The Launch Of Raloxifene HCl Tablets, USP In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Raloxifene HCl Tablets, USP In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista ® (raloxifene...

Dr. Reddy's Q2 And H1 FY17 Financial Results

Dr. Reddy's Q2 And H1 FY17 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q2 FY17 Results On Oct 25, 2016; Earnings Call Slated For Oct 25, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q2 FY17 Results On Oct 25, 2016; Earnings Call Slated For Oct 25, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Second Quarter ended September 30, 2016 on Tuesday, October 25, 2016 after the Board Meeting.

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

India drugmaker Intas will pay about $770 million for the UK and Ireland generics assets.

Dr. Reddy's Expands Strategic Collaboration With Amgen In India

Dr. Reddy's Expands Strategic Collaboration With Amgen In India

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Listed On Dow Jones Sustainability Indices 2016

Dr. Reddy's Listed On Dow Jones Sustainability Indices 2016

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Announces The Launch Of Bupropion HCl Extended-Release Tablets, USP (SR) In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Bupropion HCl Extended-Release Tablets, USP (SR) In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic...

Dr. Reddy's Announces Purple Health, A Unique Patient-Centric Platform That Takes Care Beyond The Pill

Dr. Reddy's Announces Purple Health, A Unique Patient-Centric Platform That Takes Care Beyond The Pill

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the launch of Purple Health, a unique platform designed to inspire patient-centric innovation and deliver solutions that address unmet...

Dr. Reddy's Laboratories Launches Nitroglycerin Sublingual Tablets USP In The U.S. Market Hyderabad, India, August 29, 2016

Dr. Reddy's Laboratories Launches Nitroglycerin Sublingual Tablets USP In The U.S. Market Hyderabad, India, August 29, 2016

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Nitroglycerin sublingual tablets USP, 0.

Changing Landscape for Generic-Drug Makers Creates Opportunities

Changing Landscape for Generic-Drug Makers Creates Opportunities

The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.

Dr. Reddy's Completes Acquisition Of Product Portfolio From TEVA

Dr. Reddy's Completes Acquisition Of Product Portfolio From TEVA

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Q1 FY17 Financial Results

Dr. Reddy's Q1 FY17 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Dr Reddy's Laboratories (RDY) as a weak on high relative volume candidate